Radical cytoreductive surgery combined with platinums - Carboplatin and cisplatin chemotherapy for advanced ovarian cancer

International Journal of Gynecological Cancer

Volumn 9, Issue 1, 1999, Pages 54-60

  Suzuki, M ^a   Ohwada, M ^a   Sekiguchi, I ^a   Sato, I ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Carboplatin; Cisplatin; Combination chemotherapy; Cytoreductive surgery; Ovarian cancer; Platinums

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CONSTIPATION; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; SECOND LOOK SURGERY; TINNITUS; TREATMENT OUTCOME;

EID: 0032971793     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.09890.x     Document Type: Article

References (28)

1. Terashima Y, Sasaki H, Yokoyama S, et al. Twenty one multicentral studies on prognosis of advanced ovarian cancer: focused on correlation between primary surgical procedure following adjuvant chemotherapies and 4 year survival rates. Acta Obstet Gynaecol Jpn 1993; 45: 363-70.
2. Levin L, Hryniuk W. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 1987; 14: 12-9.
3. Trump DL, Germ JL, Tutsch KD, et al. Platinum analogue combination chemotherapy: cisplatin and carboplatin - A phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol 1987; 5: 1281-9.
4. Gershenson DM, Morris M, Burke TM, et al. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. Gynecol Oncol 1995; 58: 349-55.
5. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: WHO, 1979; 23-4.
6. Blessing JA. Design, analysis, and interpretation of chemotherapy trials in gynecologic cancer. In: Deppe G, ed. Chemotherapy of Gynecologic Cancer, 2nd edn. New York: Wiley-Liss, 1990; 63-97.
7. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-20.
8. Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukada Y, Emrich LJ. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988; 6: 983-9.
9. de Gramont A, Demuynck B, Varette C, et al. Sequential cisplatin-doxorubicin, early debulking surgery and intraperitoneal chemotherapy in advanced ovarian cancer. Eur J Cancer 1992; 28: 53-8.
10. Guidozzi F, Ball JHS. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994; 53: 326-30.
11. Baker TR, Piver MS, Hempling RE. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 1994; 74: 656-63.
12. Eisenkop SM, Nalick RH, Wang H-J, Teng NNH. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993; 51: 224-9.
13. Potter ME, Partridge EE, Hatch KD, Soong S-J, Austin JM, Shingleton HM. Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 1991; 40: 195-200.
14. Hunter RW, Alexander NDE, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992; 166: 504-11.
15. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990; 38: 203-9.
16. Griffiths CT, Fuller AF. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 1978; 58: 131-42.
17. Wils JA. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Oncology 1990; 47: 115-20.
18. Lund B, Hansen M, Hansen OP, Hansen HH. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1989; 7: 1469-73.
19. Hardy JR, Wiltshaw E, Blake PR, et al. Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma. Ann Oncol 1991; 2: 131-6.
20. Segelov E, Stuart-Harris R, Bell D, Tattersall M, Hutton-Potts J, Friedlander M. A phase II study of carboplatin and cisplatin in advanced ovarian cancer. Eur J Gynaecol Oncol 1994; 15: 277-82.
21. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1984; 11: 251-63.
22. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 1589-99.
23. Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996; 14: 351-6.
24. Piccart MJ, Nogaret JM, Marcelis L, et al. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. J Natl Cancer Inst 1990; 82: 703-7.
25. Fanning J, Hilgers RD. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer. Gynecol Oncol 1993; 51: 182-6.
26. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
27. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 1994; 12: 1748-53.
28. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.